Healthcare [ 10/13 ] | Biotechnology [ 67/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 23 | -48 Decreased by -810.82% | -7.98 Decreased by -501.5% |
| Aug 14, 23 | -0.92 Increased by +85.85% | -2.89 Increased by +68.17% |
| Apr 17, 23 | -1.31 Increased by +81.29% | -1.48 Increased by +11.49% |
| Mar 1, 23 | -1.96 Increased by +87.35% | -1.48 Decreased by -32.43% |
| Nov 14, 22 | -5.27 Increased by +73.65% | -2.37 Decreased by -122.36% |
| Aug 15, 22 | -6.5 Increased by +69.05% | 5.5 Decreased by -218.18% |
| May 16, 22 | -7 Increased by +69.57% | 5.5 Decreased by -227.27% |
| Mar 31, 22 | -15.5 Increased by +31.11% | 11.5 Decreased by -234.78% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 124.49 K Decreased by -61.47% | -9.75 M Decreased by -0.24% | Decreased by -7.83 K% Decreased by -160.18% |
| Jun 30, 23 | 220.98 K Increased by +2.92% | -5.68 M Increased by +4.17% | Decreased by -2.57 K% Increased by +6.88% |
| Mar 31, 23 | 185.6 K Decreased by -11.74% | -8.73 M Decreased by -45.42% | Decreased by -4.7 K% Decreased by -64.76% |
| Dec 31, 22 | 185.6 K Increased by +76.7% | -8.18 M Increased by +65.98% | Decreased by -4.41 K% Increased by +80.75% |
| Sep 30, 22 | 323.13 K Increased by +N/A% | -9.72 M Increased by +0.39% | Decreased by -3.01 K% Decreased by N/A% |
| Jun 30, 22 | 214.72 K Increased by +N/A% | -5.93 M Increased by +4.04% | Decreased by -2.76 K% Decreased by N/A% |
| Mar 31, 22 | 210.28 K Increased by +N/A% | -6 M Increased by +5.93% | Decreased by -2.85 K% Decreased by N/A% |
| Dec 31, 21 | 105.03 K Increased by +N/A% | -24.05 M Decreased by -413.82% | Decreased by -22.9 K% Decreased by N/A% |
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.